Cost-of-illness study for the treatment of COPD in Germany;Krankheitskosten von COPD in Deutschland

Pneumologie

Volumn 58, Issue 12, 2004, Pages 837-844

  Nowak, Dennis ^a   Dietrich, E S ^b   Oberender, P ^c   Uberla K ^d   Reitberger, U ^e   Schlegel, C ^e   Albers, F ^f   Ruckdaschel S ^f   Welsch, R ^g  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Kassenarztliche Bundesvereinigung   (Germany)

^c UNIVERSITY OF BAYREUTH   (Germany)

^d University of Heidelberg   (Germany)

^e Kendle International Inc   (Germany)

^f PFIZER INC   (United States)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST OF ILLNESS; DATA ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GERMANY; HEALTH ECONOMICS; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; RESOURCE ALLOCATION; RETIREMENT;

COST OF ILLNESS; GERMANY; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 11244328142     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830143     Document Type: Article

References (28)

1. GOLD-Workshop. Global initiative for chronic obstructive lung disease. http://www.goldcopd.com/workshop, 2003
2. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349 (9064): 1498-1504
3. Nowak D, Konietzko N (Hrsg). Bronchitis. München: Urban und Schwarzenberg Verlag, 1995: 233-253
4. Rychlik R, Pfeil T, Daniel D et al. Socioconomic relevance of acute exacerbations of chronic bronchitis in the Federal Republic of Germany. A prospective cost of illness study. Dtsch Med Wochenschr 2001; 126 (13): 353-359
5. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117 (2) Supplement: 5S-9S
6. ATS statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: 77-120
7. Sachverständigenrat. Bedarfsgerechtigkeit und Wirtschaftlichkeit. Band III, Über-, Unter- und Fehlversorgung. (http://www.svr-gesundheit.de), 2000/2001
8. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117/5: 398-401
9. Stang P, Lydick E, Silberman C et al. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 2000; 117 (5 Suppl 2): 354S-359S
10. Bakke PS, Baste V, Hanoa R et al. Prevalence of obstructive lung disease in a general population: relation to occupation title and exposure to some airborne agents. Thorax 1991; 46: 863-870
11. Viegi G, Scognamiglio A, Baldacci S et al. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001; 68: 4-19
12. Lawrence AD, Keaney NP. Classification of COPD patients using airflow limitation significantly underestimates the clinical impact of the disease. Poster at the ATS. Abstract published in Am J Respir Crit Care Med 2002; 165: A442
13. Hilleman DE, Dewan N, Malesker M et al. Pharmacoeconomic evaluation of COPD. Chest 2000; 118: 1278-1285
14. Vincken W, Noord JA van, Greefhorst APM et al. Improved health outcomes in patientes with COPD during lyr's treatment with tiotropium. Eur Respir J 2002; 19: 209-216
15. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224
16. Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456
17. Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81
18. MediPlus Pro IMS. Version 4.2.17. Stand 09/02
19. Worth H, Buhl R, Cegla U et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 2002; 56: 704-738
20. Kornmann O, Beeh KM, Beier J et al. Global Initiative for Obstructive Lung Disease. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration 2003; 70 (1): 67-75
21. Dietrich ES, Schoop S, Bartmann P et al. Arzneimitteltherapie in Deutschland - Bedarf und Realität. KBV-Kontext Nr. 21 2003: 59
22. Behr J, Nowak D. Tobacco smoke and respiratory disease. In: d'Amato G, Holgate ST (Eds). The impact of air pollution on respiratory health. European Respiratory Monograph, 2002; 21 (7): 161-179
23. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404
24. Oostenbrink JB, Rutten-van Molken MP, Al MJ et al. One-year cost-effctiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241-249
25. Bürge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1349
26. 1 in patients with chronic obstructive pulmonary disease. A meta-anaylsis. Ann Intern Med 2003; 138: 969-973
27. Spencer S, Calverley PM, Burge PS et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698-702
28. Behnke M, Jörres RA, Kirsten D et al. Clinical benefits of a combined hospital and home-based exercise programme over 18 months in patients with severe COPD. Monaldi Arch Chest Dis 2003; 59: 44-51